UBS O'Connor’s Denali Therapeutics DNLI Stock Holding History

UBS O'Connor’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-50,000	Closed	-$30K	–	571
2024 Q1	$30K	Buy	+50,000	New	+$940K	﹤0.01%	456

Other funds holding DNLI

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

UBS O'Connor's DNLI Position: Q1 2025 in Review

UBS O'Connor sold out of Denali Therapeutics (DNLI) in Q1 2025, closing a stake of 21,039 shares — an estimated $429K sold.

UBS O'Connor first reported a position in DNLI in Q1 2020 and held it in 8 quarters. The position peaked at $1.44M in Q2 2023. 222 funds tracked by Wall St. Rank hold DNLI as of Q1 2025.

UBS O'Connor reported no remaining Denali Therapeutics position as of Q1 2025 after selling out during the quarter.
UBS O'Connor sold 21,039 Denali Therapeutics shares in Q1 2025, an estimated $429K.
UBS O'Connor first reported a position in Denali Therapeutics in Q1 2020 and held it in 8 quarters.
UBS O'Connor's Denali Therapeutics position peaked at $1.44M in Q2 2023.
222 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2025.

Based on UBS O'Connor's 13F filing for Q1 2025, filed 15 May 2025.